BostonGene Receives Frost & Sullivan's 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms
Recognition highlights BostonGene's leadership in improving drug development decisions,reducing risk and accelerating patient impact Frost &…


